MS target

CCARL works with scientists and clinicians to develop algorithms for detection of transcriptomes specific to various types of multiple sclerosis and responses to disease-modifying therapies.   CCARL seeks collaborations with scientists and clinicians to make more comprehensive database of MS transcriptomes.

We aim to develop a new platform, using algorithms similar to those of the OncoFinder, that would allow to perform comprehensive analysis of pathways altered by MS. This will further allow us to rank available drugs in a personalized manner, thus making the management of this disease efficient and cost-effective, and potentially side effect-free.